StockWatch
·
Pharmaceutical Preparations
Quarterly ResultNov 18, 2026, 08:45 AM

Apimeds Pharmaceuticals Q3 Revenue $2.89M; Completes Tech Transition

AI Summary

Apimeds Pharmaceuticals US, Inc. reported third quarter 2026 revenue of $2.89 million, a significant increase from no revenue in the prior year, driven by software development and deployment services. The company also reported an operating income of $2.0 million and a net income of $33.6 million, which included a substantial unrealized gain on digital assets. Apimeds has completed its transition to a technology infrastructure business, disposing of its biopharmaceutical subsidiary. Recent developments include new enterprise client agreements, a joint venture in Bermuda, and the appointment of a new CFO. However, the company's liquidity position and upcoming debt maturity raise substantial doubt about its ability to continue as a going concern.

Key Highlights

  • Revenue of $2.89 million in Q3 2026, compared to no revenue in Q3 2025, primarily from software services.
  • Operating income of $2.0 million for Q3 2026.
  • Net income of $33.6 million in Q3 2026, including a $25.26 million unrealized gain on digital assets.
  • Total assets of $153.5 million and shareholders' equity of $140.5 million as of September 30, 2026.
  • Completed business transition with disposal of biopharmaceutical subsidiary on July 14, 2026.
  • Signed technology services agreements with AQUAE Holdings, Flash Sports & Media Holdings, and BlockAssure Inc.
  • Entered into a joint venture with Skalup Capital for an insurance and technology business in Bermuda.
  • Eric Sherb appointed Chief Financial Officer effective October 1, 2026.